Sign in to view content

Masked Safety Data from ZETA-1, an Ongoing 24-Week Phase 2 Clinical Trial of APX3330, an Oral Therapeutic Being Developed for the Treatment of Diabetic Retinopathy

Michael J Allingham, MD, PhD

Video
Published 2022

Related

Patients Ultra-Responsive to Ranibizumab (RBZ): Rates of >4-Step Improvement in Diabetic Retinopathy Severity in DRCR.net Protocol S
Allen Chiang, MD, FASRS
Updates from the Field
2019
Common Age-Related Macular Degeneration Genetic Risk Variants and Geographic Atrophy Lesion Growth in the Chroma and Spectri Phase 3 Lampalizumab Trials
Karl G. Csaky, MD, PhD
Annual Meeting Talks
2018
Retinal Nonperfusion and Anti-VEGF Therapy in Diabetic Retinopathy: What We Know and What We Don’t Know
Dante Joseph Pieramici, MD
Updates from the Field
2017

Category: Diabetic Retinopathy

See more